Member Info for Sangijuelas1

It's looking more and more like the price was manipulated with a near 50% drop to allow the Longevity deal to be done at a price favourable to the likes of Steve Oliveira.
One of the big traders on OTC Markets is Citadel Llp and I think I have heard their name mentioned with regard to a short position on 4D

watching the 1hr long presentation with q & a on the Micro RX platform on the 4D website?

Article titled the Microbiome Revolution

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4191014/

Article from 3 years ago.

Microbiome Science Could Bring a Revolution in Medical Care
https://www.google.com/amp/s/www.nbcnews.com/mach/amp/ncna710861

That price showing is from Wednesday. There have been no trades since then.
There is nothing to see here

This is an alternative exchange run by OTC Markets with no listing requirements. Normally used by brokers and dealers. They claim that can increase liquidity in listed stock. Maybe explains the recent increase in automated trades?
https://www.otcmarkets.com/

More info here on the type of market it is.
https://www.investopedia.com/terms/p/pinksheets.asp

It was an article quoting Mike Barrett of the Lang Cat platform consultancy.
Title: Hargreaves Lansdown suffers system outage amid record trading volumes.

The FT article was in reference to HL failings that day

I would complain to Ombudsman if that's their final response.
FT had an article about how FCA are likely to take it very seriously that platforms can't fulfil their obligations and T & Cs not enough to turn down complaints.

If you look at the 5 day chart for it there was a weird spike to 11.5 so maybe it was that

Google was showing that. Now it's not. It was not an attempt to mislead anyone as it doesn't really mean anything anyway.

There seems to be a paradigm shift happening in medicine. A bit like the shift from the miasma theory of disease to the germ theory and 4D is the market leader.

Is up 6.4% today to its highest ever price

This is where the Merck/4D vaccine collaboration is taking place.
https://www.biospace.com/article/releases/merck-and-co-opens-cambridge-exploratory-science-center-plans-to-hire-30-more-employees-/

I can't help wondering if they are looking at cancer vaccines

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676259/

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and VelosBio Inc. today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion in cash, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively.

“At Merck, we continue to bolster our growing oncology pipeline with strategic acquisitions that both complement our current portfolio and strengthen our long-term growth potential,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “Pioneering work by VelosBio scientists has yielded VLS-101, which in early studies has provided notable evidence of activity in heavily pretreated patients with refractory hematological malignancies, including mantel cell lymphoma and diffuse large B-cell lymphoma.”

In October 2020, VelosBio announced the initiation of a Phase 2 clinical trial (NCT04504916) to evaluate VLS-101 for the treatment of patients with solid tumors, including patients with triple-negative breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer, and non-squamous non-small-cell lung cancer (NSCLC). In early clinical trials, VLS-101 demonstrated a manageable safety profile and early signs of anti-tumor activity. Results of a Phase 1 clinical trial, to be presented virtually at the 62nd American Society of Hematology Annual Meeting (Dec. 5-8, 2020), showed that VLS-101 resulted in objective clinical responses, including complete responses, in 47% (n=7/15) of patients with mantle cell lymphoma (MCL) and 80% (n=4/5) of patients with diffuse large B-cell lymphoma. Patients in this Phase 1 trial had been heavily pretreated with other anticancer medications, and their cancers had failed to respond or had relapsed after initially responding to these other anticancer medications. In addition, VelosBio is developing a preclinical pipeline of next-generation ADCs and bispecific antibodies targeting ROR1 with the potential to complement VLS-101 by offering alternative methods of tumor cell killing.
https://velosbio.com/news-events/merck-to-acquire-velosbio

August 2020
VelosBio Inc. (“VelosBio”), a clinical-stage biopharmaceutical company committed to developing novel, first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track and Orphan Drug designation for VLS-101 for the treatment of patients with mantle cell lymphoma (MCL). VLS-101 is a ROR1-directed antibody-drug conjugate (ADC) that is currently being studied in a first-in-human Phase 1 clinical trial in patients with relapsed or refractory hematologic cancers.
FDA Fast Track designation is a program designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, with the goal of getting important new drugs to patients earlier. Fast Track designation also confers important benefits to the sponsor, including potential eligibility for Priority Review of a New Drug Application, if relevant criteria are met

https://velosbio.com/news-events/velosbio-announces-fda-fast-track-and-orphan-drug-designations-for-vls-101-in-patients-with-mantle-cell-lymphoma

The current Longevity Shareholders have the right to redeem their shareholding in Longevity, even if the requisite majority of Longevity Shareholders approve the Merger. US$14.6 million is currently held in a trust account by Longevity to fund redemptions. Any redemptions by Longevity Shareholders would reduce the capital available to the Enlarged Group. Backstop agreements have therefore been executed by Longevity, the Company and Whale with certain investors, including Duncan Peyton and Alex Stevenson, (together the "Backstop Investors").

The Backstop Investors have committed to subscribe for Longevity Shares prior to Completion so as to raise up to US$14.6 million in the event of redemptions by Longevity Shareholders. To secure the Backstop Arrangements, Longevity has agreed to allot 700,000 Longevity Shares to the Backstop Investors, Whale has agreed to transfer 200,000 Longevity Shares to the Backstop Investors, and the Company has agreed to allot up to 7,530,000 4D Ordinary Shares to the Backstop Investors if and to the extent outstanding warrants issued by Longevity are exercised.

Merger deal is a formality. It's a Spac. The Spac sponsors are in. Done deal.

That's why there's a meeting in the 1st place

If its a life prolonging treatment with urgent medical need it could be brought forward